Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  07/03/2013
 
Dynavax Technologies Corporation
(Exact name of registrant as specified in its charter)
 
Commission File Number:  001-34207
 
Delaware
  
33-0728374
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)
 
(510) 848-5100
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
 
Effective July 3, 2013, the Board of Directors (the "Board") of Dynavax Technologies Corporation ("Dynavax" or the "Company") appointed Natale Ricciardi as a Class II director to serve until the 2014 Annual Meeting of Stockholders. Pursuant to the terms of an offer letter between Dynavax and Mr. Ricciardi and the compensation policies of Dynavax with respect to outside directors, Mr. Ricciardi received the following as of his date of appointment:

1.   Pursuant to the Dynavax 2004 Non-Employee Directors' Option Plan (the "Directors' Plan"), Mr. Ricciardi was granted an initial non-qualified stock option to purchase 20,000 shares of Dynavax common stock, with an exercise price equal to the fair market value on the date of grant, vesting over four years in equal annual installments;

2.   Pursuant to the Directors' Plan, Mr. Ricciardi will be eligible to receive a non-qualified option to purchase up to an additional 17,500 shares of Dynavax common stock at each annual meeting of Dynavax's stockholders (with respect to the first such grant, the option will be pro-rated such that the fraction of such 17,500 shares shall equal the fraction of the year that he serves until the 2014 annual meeting), with an exercise price equal to the fair market value on the date of grant, vesting on the first anniversary of the grant; and

3.   Mr. Ricciardi will receive an annual retainer of $40,000, payable in equal quarterly installments in arrears.

A copy of the press release relating to Mr. Ricciardi's appointment is attached hereto as Exhibit 99.1.

 
 
Item 9.01.    Financial Statements and Exhibits
 
(d) Exhibits

Exhibit No.        Description

99.1                Press Release, dated July 8, 2013, titled "Dynavax Appoints Natale Ricciardi to its Board of Directors".
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
           
Dynavax Technologies Corporation
 
 
Date: July 08, 2013
     
By:
 
/s/    Jennifer Lew
               
Jennifer Lew
               
VP, Finance
 
 

 

EXHIBIT INDEX
 
Exhibit No.
  
Description
EX-99.1
  
Dynavax Appoints Natale Ricciardi to its Board of Directors.